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Diabetic peripheral neuropathy (DPN) and diabetic kidney disease (DKD) are common diabetic complications with limited treatment options. Experimental studies show that targeting inflammation using chemokine receptor (CCR) antagonists ameliorates DKD, presumably by reducing macrophage accumulation or activation. As inflammation is implicated in DPN development, we assessed whether CCR2 and CCR5 antagonism could also benefit DPN. Five-week-old ob/ ob mice were fed a diet containing MK-0812, a dual CCR2-CCR5 receptor antagonist, for 8 weeks; DPN, DKD and metabolic phenotyping were then performed to determine the effect of CCR inhibition. Although MK-0812 reduced macrophage accumulation in adipose tissue, the treatment had largely no effect on metabolic parameters, nerve function or kidney disease in ob/ob mice. These results conflict with published data that demonstrate a benefit of CCR antagonists for DKD and hyperglycaemia. We conclude that CCR signaling blockade is ineffective in ob/ob mice and suspect that this is explained by the severe hyperglycaemia found in this model. It remains to be determined whether MK-0812 treatment, alone or in combination with improved glycaemic control, is useful in preventing diabetic complications in alternate animal models.
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| INTRODUCTION
Systemic inflammation, primarily driven by adipose tissue dysfunction, is recognized as an underlying contributor to the development of type 2 diabetes (T2D). 1 Inflammation is also implicated in diabetic kidney disease (DKD) and diabetic peripheral neuropathy (DPN), 2 common microvascular complications of T2D. 2, 3 As T2D patients manifest with hyperglycaemia, current prevention strategies focus on glycaemic control; however, this approach does not guarantee protection from DKD or DPN. 4, 5 Thus, targeting inflammation may provide an adjuvant therapy for the prevention of diabetic complications.
A hallmark of DKD is leukocyte accumulation, including macrophages, within the kidney glomerulus where they secrete proinflammatory proteins such as tumor necrosis factor alpha (TNFα), promoting inflammation and subsequent kidney injury. 3 Indeed, macrophage accumulation strongly correlates with renal dysfunction in patients with DKD. 6 Although not as well characterized, studies support a similar inflammatory mechanism in DPN. 7, 8 During initial tissue injury, resident leukocytes become activated and secrete chemokines that bind to chemokine receptors (CCRs)
found on circulating leukocytes. This chemokine-CCR signaling facilitates trafficking of circulating leukocytes to the site of injury where they propagate inflammation. Unlike inflammation triggered by external pathogens, metabolic inflammation is difficult to resolve, leading to low-grade, chronic activation of the immune response. 1 Sustained inflammation promotes leukocyte accumulation in the damaged tissue, the continued production of pro-inflammatory mediators, and amplification of the inflammatory response via a positive feedback loop. Chemokine C-C ligand-2 (CCL2) is responsible for recruiting CCR2-expressing leukocytes, including macrophages, to sites of inflammation. Antagonizing CCL2 signaling attenuates features of T2D in mouse models by preventing leukocyte infiltration into adipose tissue. 9 Importantly, these benefits appear to extend to diabetic complications, as CCR2 antagonism reduces renal tissue inflammation and ameliorates DKD in mouse models of T2D. 10 Likewise, in patients with DKD, treatment with a CCR2 antagonist or an inhibitor of CCL2/MCP1 can reduce proteinuria. 11 Though less well studied, CCL5-CCR5-mediated signaling has also been implicated in T2D
patients and rodent models of DKD
12
; however, unlike DKD, CCR2
and CCR5 activation in DPN has not yet been examined.
We recently completed microarray gene expression analyses and reported that biological pathways related to inflammation, including chemotaxis, immune response and response to wounding, are dysregulated in the sciatic nerve of ob/ob and db/db mice. 13 Moreover, the expression levels of chemokines Ccl2, Ccl4 and Ccl8, ligands for CCR2
and CCR5, were increased in sciatic nerve tissue of ob/ob mice. These data suggest that, similar to DKD, chemokine-CCR signaling is involved in DPN. Therefore, we tested whether blocking CCR2-and CCR5-mediated chemokine signaling would prevent DPN as well as DKD in ob/ob mice, a mouse model of both microvascular complications.
13,14
2 | RESEARCH DESIGN AND METHODS
| Animals and diets
Male ob/+ and ob/ob mice (BTBR.Cg-Lepob/WiscJ) were fed a standard diet (11.5% kcal fat) or a diet containing MK-0812 (10 mg/kg/ mouse) ad libitum from 5 to 13 weeks of age. Fasting blood glucose (FBG), percent glycated haemoglobin (%GHb) and plasma insulin were measured at study conclusion. Additional details into experimental procedures are described in Appendix S1, Supporting Information.
Details on the pharmacokinetic profile (Table S2 ) and primer sequences for gene expression analysis (Table S3) 
| Statistical analysis
Error bars represent SEM (n = 6 mice/group). A P value of <.05 was considered statistically significant.
3 | RESULTS 3.1 | MK-0812 treatment does not affect FBG, % GHb, insulin or body weight
At 13 weeks, ob/ob mice had increased FBG, %GHb and insulin when compared to non-diabetic controls ( Figure 1A ,B,F). Body weight was similar in ob/+ and ob/ob mice ( Figure 1C) ; however, the increase in total adipose tissue mass in ob/ob mice ( Figure 1D ) suggests that ob/ + mice have greater lean muscle mass. MK-0812 had no effect on FBG, weight, total adipose mass or insulin levels in ob/+ or ob/ob mice ( Figure 1A ,C,D,F) and only a modest effect on %GHb ( Figure 1B) . Moreover, MK-0812 treatment increased eWAT mass in ob/ob mice ( Figure 1E ). 
| MK-0812 treatment does not prevent development of diabetic microvascular complications

| DISCUSSION
Recruitment of leukocytes to kidney tissue during T2D is an early event in the pathogenesis of DKD, 10 and evidence suggests a similar mechanism in DPN. 2 Previously, we reported that ob/ob mice develop an early and robust DPN, with transcriptomic bioinformatics analysis implicating "chemotaxis" and "inflammatory response" in DPN pathogenesis. 13 As these animals manifest with early DKD, 14 FIGURE 2 Effects of MK-0812 on DPN and DKD. Neuropathy phenotyping consisted of measuring latency of hindpaw withdrawal from a thermal stimulus (A), quantification of intraepidermal nerve fiber (IENF) density (B) and assessment of sural sensory (C) (SNCV) and sciatic motor (D) (MNCV) nerve conduction velocity. Nephropathy was assessed by urinary ACR (E), urine volume (F), mesangial index, expressed as PAS-positive glomerular area divided by total glomerular area (G) and total glomerular area (H). **P < .001; ***P < .0001 ob/ob mice vs ob/+ mice. δδP < .001 MK-0812-treated ob/+ and ob/ob mice vs respective non-treated controls the current study sought to investigate whether targeting a common inflammatory pathway would have restorative effects by attenuating microvascular complications.
Contrary to our hypothesis, MK-0812 treatment evoked no improvement in DKD or DPN in ob/ob mice and was also insufficient in mitigating hyperglycaemia or hyperinsulinaemia. Despite the absence of predicted effects, however, MK-0812 decreased adipose inflammation in ob/ob mice by reducing concentrations of Cd68, F4/ 80 and Tnfα. 13 MK-0812-treated ob/ob mice also displayed a modest decrease in %GHb relative to untreated controls that could be attributed to the decrease in adipose tissue inflammation, but the improvement was insufficient to surmount the metabolic derangements characteristic of T2D. 10 These results conflict with independent studies in which CCR2 inhibition prevented DKD in mice 10 and humans. db/db mice, 10 we observed a decrease in inflammatory markers following MK-0812 treatment in ob/ob mice, thus confirming that the lack of MK-0812 therapeutic efficacy on microvascular complications in ob/ob mice was not simply the result of inadequate drug activity.
In summary, MK-0812 had no effect on the metabolic parameters or the severity of DPN and DKD in ob/ob mice. These observations are unexpected, given previous independent reports of its efficacy in improving both glycaemic control and DKD in db/db mice. 10 We speculate that MK-0812 treatment in alternate models, such as db/db or diet-induced obese mice, should be pursued, based on the existing literature supporting a role for inflammation in the onset and development of microvascular complications in humans as well as these other models.
